Vitrolife — AGM Information 2010

Apr 27, 2010

Press release April 27, 2010 Gothenburg, Sweden

Report from Annual General Meeting

At Vitrolife's Annual General Meeting yesterday, April 26, the following, amongst other things, was decided:

• The Board's proposed dividend of SEK 0.50 for the financial year 2009 was approved. April 29, 2010 was adopted as the record day.
• Re-election of Board members Patrik Tigerschiöld, Fredrik Mattsson, Madeleine Olsson-Eriksson, Tord Lendau, Maris Hartmanis and election of Barbro Fridén, in accordance with the election committee's proposal.
• Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to take a decision on the issue of a maximum of 1,950,000 shares in total, corresponding to approximately 10 percent of the company's share capital.
• The Board was authorized to take a decision, up until the next Annual General Meeting and on one or more occasions, with regard to the acquisition and transfer of the company's own shares, at the most 10 percent of the company's shares.
• The proposed principles for remuneration and other conditions of employment for the senior management were approved.

At the Board meeting following election which was held after the Annual General Meeting, Patrik Tigerschiöld was elected Chairman of the Board.

April 27, 2010 Gothenburg, Sweden The Board

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 61 Eva Nilsagård, CFO, phone +46 31 721 80 13

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

________________________________________________________________________________________

Vitrolife today has approximately 170 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

_________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Tuesday April 27, 2009 at 8.00 am.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.